NCT01273103View on ClinicalTrials.gov

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2011

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

200mg [14C]- GSK2248761

single oral suspension dose of \[14C\]- GSK2248761 200 mg

Trial Locations (1)

53704

GSK Investigational Site, Madison

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY

NCT01273103 - A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects | Biotech Hunter | Biotech Hunter